American Retired Seniors

Just another WordPress site

Ideamensch’s Interview with Clay Siegall

Clay Siegall is one of the most humble people you will have the privilege of meeting. Even with his massive success in biotechnology, one of the most complex field, he still finds time to seat down on an interview. In April, 2017, he was interviewed by Ideamensch on his company, Seattle Genetics. The first question was of course what inspired Seattle Genetics. Clay Siegall responded that since he was a young man, he wanted to do this. He wanted to help patients by improving the available oncological tools. His passion for the industry had been sparked as he watched his father slowly die of cancer. He vowed that he would dedicate his life so that each and every day there is a better tool to deal with this beast. He has been doing this for the past 3 decades and Seattle Genetics gave him an opportunity to optimize his potential.


He explained to Ideamensch of how ant every stage of life you come to a realization that there is just so much that you don’t know. But, the key to success is to interacting with the smartest people in your industry and always ensuring that you learn something from them. Siegall also talked to Ideamensch on his best strategies. he said that he had successfully led Seattle Genetics through making strategic collaboration, like the collaboration with Takeda Pharmaceutical Company, the company successfully got their new FDA-approved ADC cancer therapy, ADCETRIS, to sell in over 65 countries.


About Clay Siegall

Clay Siegall is one of the most prominent scientists. He graduated from the University of Maryland with a BS in Zoology. He also attained a doctorate degree in Genetics, from the George Washington University. Siegall was persistent in getting education knowledge that would be instrumental in the career that he had planned ahead.


In the year 1988, Clay Siegall began working for National Cancer Institute, National Institutes of Health. He worked for the company for a period of three years before being tapped into Bristol-Myers Squibb Pharmaceutical Research Institute, where he worked for the next six years before co-founding Seattle Genetics.